Recognition of Non-Operating Income and Expenses
Medrx Co.,Ltd., and its wholly owned subsidiary MEDRX AUSTLARIA PTY LTD
Grant income under Australia's research and development tax incentive scheme, and the 35th Series Stock Acquisition Rights with Exercise Price Revision Clauses
The grant income arose because MEDRX AUSTLARIA PTY LTD received a grant under Australia's research and development tax incentive scheme. The share issuance costs consisted of registration fees and other expenses associated with the issuance and exercise of the 35th Series Stock Acquisition Rights with Exercise Price Revision Clauses.
Grant income: ¥82 million (non-operating income); share issuance costs: ¥1 million (non-operating expenses)
The nine months ended the third quarter of the fiscal year ending December 2026 (1 January 2026 to 30 September 2026)
Refer to the "Summary of Financial Results for the Nine Months Ended 30 September 2026 [Japanese GAAP] (Consolidated)" released today (13 November 2026)
| Item | Details |
|---|---|
| Event name | Recognition of Non-Operating Income and Expenses |
| Date of occurrence | 1 January 2026–30 September 2026 (the nine-month consolidated cumulative period ended 30 September 2026; no specific recognition date stated) |
| Subject Entity | Medrx Co.,Ltd., and its wholly owned subsidiary MEDRX AUSTLARIA PTY LTD |
| Target Locations / Products | Grant income under Australia's research and development tax incentive scheme, and the 35th Series Stock Acquisition Rights with Exercise Price Revision Clauses |
| Cause | The grant income arose because MEDRX AUSTLARIA PTY LTD received a grant under Australia's research and development tax incentive scheme. The share issuance costs consisted of registration fees and other expenses associated with the issuance and exercise of the 35th Series Stock Acquisition Rights with Exercise Price Revision Clauses. |
| Amount of Impact on Business Performance | Grant income: ¥82 million (non-operating income); share issuance costs: ¥1 million (non-operating expenses) |
| Accounting period in which recognized | The nine months ended the third quarter of the fiscal year ending December 2026 (1 January 2026 to 30 September 2026) |
| Impact on Earnings Forecast | Refer to the "Summary of Financial Results for the Nine Months Ended 30 September 2026 [Japanese GAAP] (Consolidated)" released today (13 November 2026) |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The grant income arose because the wholly owned subsidiary received a grant under Australia's research and development tax incentive scheme. The share issuance costs consisted of registration fees and other expenses associated with the issuance and exercise of the 35th Series Stock Acquisition Rights with Exercise Price Revision Clauses.